Category: 3. Business

  • Babies who drank ByHeart formula got sick months before botulism outbreak, parents say

    Babies who drank ByHeart formula got sick months before botulism outbreak, parents say

    As health officials investigate more than 30 cases of infant botulism linked to ByHeart baby formula since August, parents who say their children were sickened with the same illness months before the current outbreak are demanding answers, too.

    California public health officials confirmed late Friday that six babies in that state who consumed ByHeart formula were treated for botulism between November 2024 and June 2025, up to nine months before the outbreak that has sickened at least 31 babies in 15 states.

    At the time, there was “not enough evidence to immediately suspect a common source,” the California Department of Public Health said in a statement.

    Even now, “we cannot connect any pre-August 1 cases to the current outbreak,” officials said.

    Parents of at least five babies said that their infants were treated for the rare and potentially deadly disease after drinking ByHeart formula in late 2024 and early 2025, according to reports shared with The Associated Press by Bill Marler, a Seattle food safety lawyer representing the families.

    Amy Mazziotti, 43, of Burbank, California, said her then-5-month-old son, Hank, fell ill and was treated for botulism in March, weeks after he began drinking bottles filled with ByHeart formula.

    Katie Connolly, 37, of Lafayette, California, said her daughter, M.C., then 8 months old, was hospitalized in April and treated for botulism after being fed ByHeart formula in hopes of helping the baby sleep.

    For months, neither mother had any idea where the infections could have originated. Such illnesses in babies typically are caused by spores spread in the environment or by contaminated honey.

    Then ByHeart recalled all of its products nationwide on Nov. 11 in connection with growing cases of infant botulism.

    As soon as she heard it was ByHeart, Mazziotti said she thought: “This cannot be a coincidence.”

    ByHeart officials this week confirmed that laboratory tests of previously unopened formula found that some samples were contaminated with the type of bacteria that leads to infant botulism.

    Marler said at least three other cases that predate the outbreak involved babies who drank ByHeart and were treated for botulism, according to their families. One consumed ByHeart formula in December 2024. The other two were sickened later in the spring, he said.

    An official with the U.S. Centers for Disease Control and Prevention said federal investigators were aware of reports of earlier illnesses but that efforts are focused now on understanding the unusual surge of dozens of infections documented since Aug. 1.

    “That doesn’t mean that they’re not necessarily part of this,” said Dr. Jennifer Cope, a CDC scientist leading the probe. “It’s just that right now, we’re focusing on this large increase.”

    Because so much time has passed and because parents of babies who got sick earlier may not have recorded lot numbers of product or kept empty cans of formula, “it will make it harder to definitively link them” to the outbreak, Cope said.

    Connolly said it feels like her daughter has been forgotten.

    “What I want to know is why did the cases beginning in August flag an investigation, but the cases that began in March did not?” Connolly said.

    Cope and other health officials said the strong signal connecting ByHeart to infant botulism cases only became apparent in recent weeks.

    Before this outbreak, no powdered infant formula in the U.S. had tested positive for the type of bacteria that leads to botulism, California health officials said. The number of cases also were within an expected range. A test of a can of open formula fed to a sick baby in the spring did not detect the bacterium.

    Then, beginning in August and through October, more cases were identified on the East Coast involving a type of toxin rarely detected in the region, officials said. More cases were seen in very young infants and more cases involved ByHeart formula, which accounts for less than 1 percent of infant formula sold in the U.S.

    Earlier this month, after a sample from a can of ByHeart formula fed to a sick infant tested positive for the germ that leads to illness, officials notified the CDC, the U.S. Food and Drug Administration and the public.

    Less than 200 cases of infant botulism are reported in the U.S. each year. The disease is caused when babies ingest spores that germinate in the gut and produce a toxin. The bacterium that leads to illness is ubiquitous in the environment, including soil and water, so the source is often unknown.

    Officials at the California Infant Botulism Treatment and Prevention Program track reports of botulism and the distribution of the only treatment for the illness, an IV medication called BabyBIG.

    Outside food safety experts said the CDC should count earlier cases as part of the outbreak if babies consumed ByHeart formula and were treated for botulism.

    “Absolutely, yes, they should be included,” said Frank Yiannas, former deputy commissioner for food policy and response at the U.S. Food and Drug Administration. “Why wouldn’t they be included?”

    Sandra Eskin, chief executive of STOP Foodborne Illness, an advocacy group, agreed.

    “This outbreak is traumatic for parents,” she said. “They may have fed their newborns and infants a product they assumed was safe. And now they’re dealing with hospitalization and serious illness of their babies.”

    Connolly and Mazziotti said their babies are improving, though they still have some lingering effects. Botulism causes symptoms that include constipation, poor feeding, head and limb weakness and other problems.

    After months of uncertainty about the potential cause of the infection, Connolly said she “became completely obsessed” with the link to ByHeart formula. Now, she just wants answers.

    “We deserve to know the data that can help us understand how our babies got sick,” she said.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

    Continue Reading

  • Can Nasdaq’s Recent Tech Partnerships Justify Its 13% 2025 Price Surge?

    Can Nasdaq’s Recent Tech Partnerships Justify Its 13% 2025 Price Surge?

    • Ever wondered if Nasdaq’s stock is truly worth its current price, or if there is untapped value beneath the surface?

    • While the share price has edged up 0.7% over the past week, it has also seen a 13.2% gain year-to-date, indicating signs of growth potential.

    • Recently, Nasdaq’s stock has attracted investor attention following notable tech partnerships and major financial market developments. These events have provided new energy and context to recent price movements, leading to speculation about future developments.

    • Currently, Nasdaq scores just 1 out of 6 on our valuation checks, so examining how different approaches assess its value may be helpful. There is also a more insightful way to consider valuation, which will be revealed by the end of this article.

    Nasdaq scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Excess Returns Model estimates a company’s value by calculating how much profit it generates above its cost of equity on invested capital. Essentially, it measures the effectiveness with which Nasdaq can grow shareholder wealth beyond what investors could expect from an average investment of similar risk.

    For Nasdaq, the model considers a Book Value of $20.99 per share and a Stable EPS of $4.09 per share. These values are derived from forward-looking analyst estimates of return on equity. The company’s Cost of Equity stands at $1.97 per share, while the calculated Excess Return is $2.12 per share. Nasdaq’s average Return on Equity is an impressive 17.65%. A stable Book Value is projected to reach $23.15 per share in coming years, according to analyst consensus.

    Applying the Excess Returns methodology, Nasdaq’s estimated intrinsic value works out to $63.52 per share. Compared to the current share price, this represents a 38.0% premium, indicating that the stock is considerably overvalued based on this approach.

    Result: OVERVALUED

    Our Excess Returns analysis suggests Nasdaq may be overvalued by 38.0%. Discover 918 undervalued stocks or create your own screener to find better value opportunities.

    NDAQ Discounted Cash Flow as at Nov 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Nasdaq.

    The Price-to-Earnings (PE) ratio is widely regarded as a reliable valuation metric for profitable companies because it allows investors to see how much they are paying for each dollar of earnings. For companies like Nasdaq, which generate consistent profits, the PE ratio provides a straightforward way to compare value against other similar businesses.

    Continue Reading

  • These under-the-radar chip stocks could deliver rapid sales growth for the next 2 years

    These under-the-radar chip stocks could deliver rapid sales growth for the next 2 years

    By Britney Nguyen and Philip van Doorn

    Nvidia isn’t the only semiconductor company with compelling revenue-growth prospects – Credo and Astera Labs are also among players expected to put up stellar numbers

    Astera Labs, Nvidia and Credo are among the chip companies with the best projected revenue-growth prospects looking out two years.

    Nvidia Corp. increased sales by 62% in its latest quarter, and analysts see more revenue momentum ahead. But investors looking for fast growth in the chip sector have a number of places to look beyond the world’s largest company.

    The artificial-intelligence trade has come under pressure in recent weeks, reflecting a flurry of concerns around factors such as the interest-rate outlook, OpenAI’s future position in the AI ecosystem and even Nvidia’s (NVDA) own swelling inventory levels.

    That means investors might need to start getting more selective when looking for AI winners. Focusing on sales-growth expectations over the next two years could be a good place to start.

    Below is a list of rapidly growing companies in the semiconductor industry. Two of them are Credo Technology Group Holding Ltd. (CRDO) and Astera Labs Inc. (ALAB), which both make high-speed connectivity components for data centers and other AI infrastructure.

    Credo and Astera Labs have been “rocket ships” in terms of customer demand because both companies are “addressing one of the key bottlenecks” in the AI buildout, which is connectivity, William Blair analyst Sebastien Naji told MarketWatch.

    Nvidia and its competitors have turned to rolling out new graphics processing units on an annual cadence, “but the actual processors themselves are still operating much faster than the rest of the system can actually process that data,” Naji said. Therefore, connectivity has become a more critical part of improving overall system performance.

    The companies stand to drive future sales growth by capitalizing on the AI-infrastructure buildout, which Nvidia Chief Executive Jensen Huang said could drive up to $4 trillion worth of spending through the end of the decade. Naji noted Astera Labs and Credo are also in the process of diversifying their businesses via a mix of new customers and product offerings.

    For instance, a new switch from Astera Labs “meaningfully increases the average sales price of the solutions that they’re selling,” he said.

    Up until last year, Amazon.com Inc. (AMZN) was Credo’s main growth driver and customer, representing about two-thirds of its revenue, Naji noted. But Credo, which sells active electrical cables, now has “five reliable hyperscaler customers,” he said. Those are are Amazon, Microsoft Corp. (MSFT), xAI, Meta Platforms Inc. (META) and Oracle Corp. (ORCL)

    At a high level, Naji acknowledges concerns about valuations. The stocks aren’t cheap relative to near-term earnings estimates, but Naji sees “plenty of pent-up” demand as well as a high likelihood of beats and raises over the next few quarters as the new products manifest more in financials.

    Screening semiconductor companies for expected sales growth

    To identify which semiconductor manufacturers are expected by analysts to increase revenue most quickly over the next two years, we began with a list of 76 companies.

    The list includes all 30 stocks in the PHLX Semiconductor Index SOX, which is tracked by the iShares Semiconductor ETF SOXX. To this we added 36 more companies in the S&P Composite 1500 index XX:SP1500 that were identified by LSEG as being in the “semiconductor” or “semiconductor equipment and testing” industries, or the “semiconductors and semiconductor equipment” Global Industrial Classification Standard group.

    Then we added 10 more industry players that are based outside the U.S. whose stocks are held within the portfolio of the iShares MSCI World ETF URTH. This exchange-traded fund tracks the MSCI World index of developed markets.

    Our screen centered on projected compound annual growth rates (CAGR) for the companies’ sales from calendar 2025 through 2027. These are based on consensus estimates among analysts working for brokerage and research firms polled by LSEG, with adjustments for companies (such as Nvidia) whose fiscal reporting periods don’t match the calendar.

    We cut the list of 76 companies to 66 for which consensus estimates through 2027 were available from groups of at least five analysts.

    Here are the 20 remaining semiconductor companies expected to grow sales most quickly from 2025 through 2027:

       Company                                       Ticker    Estimated sales CAGR from 2025 through 2027  Forward P/E 
       Astera Labs Inc.                             ALAB                                             40.2%         60.8 
       SiTime Corp.                                 SITM                                             36.7%         61.0 
       Nvidia Corp.                                 NVDA                                             36.5%         25.1 
       Credo Technology Group Holding Ltd.          CRDO                                             36.3%         55.7 
       BE Semiconductor Industries N.V.             NL:BESI                                          35.1%         40.0 
       Advanced Micro Devices Inc.                  AMD                                              35.1%         32.8 
       Broadcom Inc.                                AVGO                                             32.3%         36.2 
       Impinj Inc.                                  PI                                               23.1%         52.9 
       Micron Technology Inc.                       MU                                               22.5%         10.8 
       ACM Research Inc.                            ACMR                                             22.0%         13.7 
       Arm Holdings PLC                             ARM                                              20.7%         62.7 
       Taiwan Semiconductor Manufacturing Co. Ltd.  TSM                                              19.0%         22.5 
       Lattice Semiconductor Corp.                  LSCC                                             19.0%         44.5 
       Allegro Microsystems Inc.                    ALGM                                             18.8%         27.2 
       Teradyne Inc.                                TER                                              18.2%         30.6 
       Marvell Technology Inc.                      MRVL                                             17.5%         23.5 
       First Solar Inc.                             FSLR                                             17.4%         11.1 
       Microchip Technology Inc.                    MCHP                                             17.3%         22.9 
       Silicon Laboratories Inc.                    SLAB                                             16.8%         45.7 
       Rambus Inc.                                  RMBS                                             16.4%         29.7 
                                                                                                           Source: LSEG 

    The table includes forward price-to-earnings ratios. These are Thursday’s closing prices divided by consensus earnings-per-share estimates for the next 12 months. In comparison, the S&P 500’s SPX forward P/E multiple is 22.8; that is lower than the P/E for all but five stocks on the list above. But the S&P 500’s projected revenue CAGR from 2025 through 2027 is a weighted 6.8%, according to LSEG, which is a low level compared with the 20 companies listed here.

    A look at some of the other top names

    Teradyne Inc. (TER), which designs and manufactures automatic testing equipment, is among the top 20 companies in the semiconductor industry with the highest projected revenue CAGR through 2027.

    When analyzing Teradyne’s earnings report in October, Morgan Stanley’s Shane Brett noted that the company’s core businesses of networking, memory and custom chips was “really strengthening.” But a big question is whether the company will get qualified by Nvidia.

    Brett sees opportunities for Teradyne to gain share in the compute-testing market, especially as the incumbent Advantest Corp. (ATEYY) (JP:6857) is seeing demand from Nvidia, Advanced Micro Devices Inc. (AMD) and Broadcom Inc. (AVGO) outpace supply, though “the timing and specific customers remain uncertain.”

    Meanwhile, memory-chip maker Micron Technology Inc. (MU), which has been among the top performers in the S&P 500 this year, should be able to build upon momentum in its business of dynamic random-access memory thanks to supply shortages.

    While Micron did not preannounce its fiscal first-quarter results during a conference appearance this week as some on Wall Street were looking forward to, UBS analyst Timothy Arcuri is upbeat about the period and the prospect of a durable cycle for high-bandwidth memory even beyond that.

    Programmable-chip maker Lattice Semiconductor Corp. (LSCC) is another semiconductor company that is expected to see a high sales CAGR through 2027. The company designs and manufactures low-power field-programmable gate arrays, or FPGAs, which are chips that can be programmed and reprogrammed after manufacturing for different tasks.

    Historically, most of Lattice’s exposure has been in the automotive and industrial markets, KeyBanc Capital Markets analyst John Vinh told MarketWatch. Those markets, however, have been in a downturn, and the expected recovery has been shallower than what investors were expecting at the beginning of the year because of uncertainties over U.S. trade policy.

    Vinh expects more meaningful recovery in the industrial market next year as the cyclical semiconductor industry comes out of an inventory-destocking cycle.

    Meanwhile, the communications and computing segment has been “the other key growth driver” for Lattice, Vinh noted, which refers to communications infrastructure and both traditional and AI data centers.

    (MORE TO FOLLOW) Dow Jones Newswires

    11-22-25 0900ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • Where Domino’s Pizza Could Be by 2025, 2026, and 2030

    Where Domino’s Pizza Could Be by 2025, 2026, and 2030

    Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

    Analysts are saying that Domino’s Pizza could decline by 2030, a bearish long-term outlook that has some investors questioning whether DPZ can maintain its dominance in a slowing pizza market. If you’re bullish and want exposure anyway, SoFi lets you trade Domino’s Pizza stock with zero commissions, and new users who fund their account can receive up to 1,000 dollars in stock. You can also earn a 1 percent bonus if you transfer your investments to SoFi and keep them there until December 31, 2025, giving investors a small kicker on top of potential returns.

    Domino’s Pizza has leaned heavily on its massive delivery network, rapid store expansion and fast-growing digital ordering system, but investors should expect continued volatility as the company chases ambitious global targets in a challenging consumer environment. Rising food and labor costs, tightening household budgets and intensifying competition continue to shape the stock’s risk–reward profile.

    Don’t Miss:

    This breakdown looks at DPZ’s 2030 forecasts, current Wall Street sentiment and the forces behind both the bullish and bearish cases.

    Wall Street currently maintains a Buy rating on Domino’s, with Benzinga reporting an average price target around 488 dollars. The most bullish target sits at 574 dollars, while the lowest is 340 dollars, reflecting a wide range of expectations driven by cost pressures and uneven demand trends.

    Year

    Bullish

    Average

    Bearish

    2025

    424.45

    403.64

    391.65

    2026

    412.19

    290.8

    231.16

    2027

    315.04

    268.93

    222.31

    2028

    407.85

    347.12

    305.06

    2029

    378.87

    340.65

    299.21

    2030

    304.17

    221.56

    176.6

    2031

    240.82

    205.67

    169.84

    2032

    311.59

    265.25

    233.06

    2033

    289.45

    260.15

    228.59

    2040

    181.86

    154.88

    136.02

    2050

    70.57

    57

    45.96

    These projections come from CoinCodex models analyzing historical trends, volatility patterns and longer-term moving averages.

    Domino’s long-term strategy remains compelling for those who believe in scalable, franchise-driven restaurant growth. The company’s aim to reach 50,000 global stores provides a clear expansion pathway, particularly in international markets where new units continue to open at a rapid pace. More than 85 percent of U.S. revenue now comes from digital ordering, giving Domino’s an efficiency edge and helping lift average order values. The franchise model also insulates the parent company from many operational risks while allowing it to generate stable, high-margin royalty and supply chain revenue.

    Meanwhile, Domino’s management has shown strong discipline in controlling costs, adjusting pricing and protecting margins during periods of inflation — all while maintaining a long history of dividend increases, signaling healthy cash flow and consistent shareholder returns.

    On the downside, Domino’s valuation remains high relative to the broader restaurant sector, leaving it vulnerable if store growth slows or international demand softens. The pizza category as a whole has shown flat growth, meaning new gains require taking share from rivals — a process that increasingly depends on expensive promotions.

    Rising ingredient and labor costs are adding pressure across the franchise network, and additional tariff-driven food basket inflation poses further challenges. Competition from third-party delivery platforms and aggressive rivals like Papa John’s is also reducing Domino’s pricing power. International performance remains a swing factor, heavily influenced by currency fluctuations and geopolitics.

    • Bullish: 424.45

    • Average: 403.64

    • Bearish: 391.65

    CoinCodex expects DPZ to trade within a relatively stable channel in 2025, with moderate volatility and no decisive long-term shift. Cost management efforts and rising digital penetration may help steady the business, though technical indicators still reflect short-term bearish pressure.

    • Bullish: 412.19

    • Average: 290.8

    • Bearish: 231.16

    The models widen substantially in 2026, pointing to dramatically higher uncertainty. Success depends heavily on the strength of international expansion — but a consumer downturn, slowing discretionary spending or rising costs could pull the stock sharply lower. This is a pivotal period for Domino’s ability to defend margins and maintain its unit growth strategy.

    • Bullish: 304.17

    • Average: 221.56

    • Bearish: 176.6

    By 2030, algorithmic forecasts point to a meaningful decline from current levels. This scenario assumes that Domino’s competitive moat weakens, potentially due to rising delivery fees, changing consumer food preferences or disruption in the broader quick-service industry.

    If competitors innovate faster or if delivery economics shift unfavorably, Domino’s long-term expansion model could face heavy pressure. On the other hand, a successful push into new markets could soften potential downside.

    Investors evaluating DPZ should focus on the durability of two core strengths: its franchise-based operating model and its digital ordering ecosystem. Domino’s supply chain and royalty revenue structure allow the business to scale without the full financial burden carried by individual operators, but this also means franchisee health is critical. Rising food, labor and tariff-driven costs could slow new store openings or strain operators’ profitability.

    Strategic partnerships — including its integration with DoorDash — may improve reach, but they also introduce new fee structures that could weigh on margins. Persistent promotions across the industry suggest that customer acquisition may become more expensive, making it harder for Domino’s to sustain past levels of high-margin growth.

    At the same time, Domino’s remains committed to shareholder returns through dividends and buybacks. Long-term investors should assess whether these capital allocation decisions are sustainable given rising costs and uneven unit economics.

    The bearish long-term forecasts through 2030 add a layer of caution. Much of Domino’s future success depends on whether it can hit its store expansion targets, maintain digital leadership and protect margins in a landscape being reshaped by delivery apps, commodity inflation and evolving consumer habits.

    For now, DPZ remains a premium-valued stock with meaningful upside drivers — and equally meaningful risks — as it navigates the next stage of global expansion.

    When evaluating any stock price forecast, it’s wise to think about portfolio balance and not rely on a single company’s trajectory. Markets shift quickly, and putting all of your capital into one sector or stock can increase risk. Many investors are turning to platforms that open the door to real estate, professional financial advice, fixed-income products, and even self-directed retirement options. These tools make it easier to diversify, smooth out volatility, and build wealth across multiple asset classes over time.

    Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100. This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly.

    For those seeking fixed-income style returns without Wall Street complexity, Worthy Bonds offers SEC-qualified, interest-bearing bonds starting at just $10. Investors earn a fixed 7% annual return, with funds deployed to small U.S. businesses. The bonds are fully liquid, meaning you can cash out anytime, making them attractive for conservative investors looking for steady, passive income.

    Self-directed investors looking to take greater control of their retirement savings may consider IRA Financial. The platform enables you to use a self-directed IRA or Solo 401(k) to invest in alternative assets such as real estate, private equity, or even crypto. This flexibility empowers retirement savers to go beyond traditional stocks and bonds, building diversified portfolios that align with their long-term wealth strategies.

    SoFi gives members access to a wide range of professionally managed alternative funds, covering everything from commodities and private credit to venture capital, hedge funds, and real estate. These funds can provide broader diversification, help smooth out portfolio volatility, and potentially boost total returns over time. Many of the funds have relatively low minimums, making alternative investing accessible.

    Range Wealth Management takes a modern, subscription-based approach to financial planning. Instead of charging asset-based fees, the platform offers flat-fee tiers that provide unlimited access to fiduciary advisors along with AI-powered planning tools. Investors can link their accounts without moving assets, while higher-level plans unlock advanced support for taxes, real estate, and multi-generational wealth strategies. This model makes Range especially appealing to high-earning professionals who want holistic advice and predictable pricing.

    For investors concerned about inflation or seeking portfolio protection, American Hartford Gold provides a simple way to buy and hold physical gold and silver within an IRA or direct delivery. With a minimum investment of $10,000, the platform caters to those looking to preserve wealth through precious metals while maintaining the option to diversify retirement accounts. It’s a favored choice for conservative investors who want tangible assets that historically hold value during uncertain markets.

    See Next:

    This article DPZ Stock Price Prediction: Where Domino’s Pizza Could Be by 2025, 2026, and 2030 originally appeared on Benzinga.com

    Continue Reading

  • Britain’s Daily Mail publisher enters exclusive talks to buy Telegraph Media Group for $654 million

    Britain’s Daily Mail publisher enters exclusive talks to buy Telegraph Media Group for $654 million

    LONDON — The publisher of Britain’s Daily Mail has entered exclusive talks to buy Telegraph Media Group in a deal that would link two news groups that have traditionally supported the right-leaning Conservative Party.

    Daily Mail and General Trust plc said on Saturday that the talks were designed to finalize the terms of a 500 million-pound ($654-million) deal to buy the Telegraph from an Abu Dhabi-backed venture known as Redbird IMI.

    The proposed transaction comes after concerns about foreign ownership of British news organizations stalled Redbird IMI’s efforts to take control of the Daily Telegraph and its sister Sunday publication two years ago.

    Culture Secretary Lisa Nandy said she would review any new acquisition to ensure it protects the public interest and complies with legislation governing “foreign state influence” in media mergers.

    DMGT said it expected to complete the transaction “quickly.”

    “Under ownership the Daily Telegraph will become a global brand, just as the Daily Mail has,” Chairman Jonathan Harmsworth, also known as Lord Rothermere, said in a statement.

    The battle over ownership of the Telegraph, a fixture on Britain’s media landscape since 1855, began in 2023, when the Barclay family lost control of the company in a dispute with its lenders.

    In November of that year, a venture between New York-based RedBird Capital and Abu Dhabi’s International Media Investments said it had agreed to acquire the Telegraph in exchange for loans that would allow the Barclays to repay their debts to Lloyds Banking Group.

    But that deal triggered a debate in the House of Commons about the dangers of foreign influence over Britain’s news media — and by extension the national political debate.

    The previous government, led by Conservative Prime Minister Rishi Sunak, quickly announced plans to review the proposed deal.

    “It would not be appropriate for a foreign state to interfere with the accurate presentation of our news or the freedom of expression in newspapers,” then-Culture Secretary Lucy Frazer said at the time.

    Continue Reading

  • The dividend yield on the S&P 500 is the lowest since the dotcom bubble

    The dividend yield on the S&P 500 is the lowest since the dotcom bubble

    Continue Reading

  • Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated kaposi’s sarcoma. Science. 1994;266:1865–9. https://doi.org/10.1126/science.7997879.

    Google Scholar 

  • Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5:9. https://doi.org/10.1038/s41572-019-0060-9.

    Google Scholar 

  • Vischer HF, Siderius M, Leurs R, Smit MJ. Herpesvirus-encoded gpcrs: neglected players in inflammatory and proliferative diseases? Nat Rev Drug Discov. 2014;13:123–39. https://doi.org/10.1038/nrd4189.

    Google Scholar 

  • De Groof TWM, Elder EG, Siderius M, Heukers R, Sinclair JH, Smit MJ. Viral G protein–coupled receptors: attractive targets for herpesvirus-associated diseases. Pharmacol Rev. 2021;73:828–46. https://doi.org/10.1124/pharmrev.120.000186.

    Google Scholar 

  • Tsutsumi N, Kildedal DF, Hansen OK, Kong Q, Schols D, Van Loy T, et al. Insight into structural properties of viral G protein-coupled receptors and their role in the viral infection: IUPHAR Review 41. Br J Pharmacol. 2025;182:26–51. https://doi.org/10.1111/bph.17379.

    Google Scholar 

  • Syrovatkina V, Alegre KO, Dey R, Huang X-Y. Regulation, signaling, and physiological functions of G-proteins. J Mol Biol. 2016;428:3850–68. https://doi.org/10.1016/j.jmb.2016.08.002.

    Google Scholar 

  • Gurevich VV, Gurevich EV. GPCR signaling regulation: the role of GRKs and arrestins. Front Pharmacol. 2019;10:125. https://doi.org/10.3389/fphar.2019.00125.

    Google Scholar 

  • Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72. https://doi.org/10.1038/nri.2017.49.

    Google Scholar 

  • Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29:10–21. https://doi.org/10.1038/s41417-021-00303-x.

    Google Scholar 

  • de Munnik SM, Smit MJ, Leurs R, Vischer HF. Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors. Front Pharmacol. 2015. https://doi.org/10.3389/fphar.2015.00040.

    Google Scholar 

  • Lyngaa R, Nørregaard K, Kristensen M, Kubale V, Rosenkilde MM, Kledal TN. Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. Oncogene. 2010;29:4388–98. https://doi.org/10.1038/onc.2010.173.

    Google Scholar 

  • Maussang D, Verzijl D, Van Walsum M, Leurs R, Holl J, Pleskoff O, et al. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci USA. 2006;103:13068–73. https://doi.org/10.1073/pnas.0604433103.

    Google Scholar 

  • Bais C, Santomasso B, Coso O, Arvanitakis L. G-protein-coupled receptor of kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86–9. https://doi.org/10.1038/34193.

    Google Scholar 

  • Yang T-Y, Chen S-C, Leach MW, Manfra D, Homey B, Wiekowski M, et al. Transgenic Expression of the Chemokine Receptor Encoded by Human Herpesvirus 8 Induces an Angioproliferative Disease Resembling Kaposi’s Sarcoma. J Exp Med. 2000;191:445–54. https://doi.org/10.1084/jem.191.3.445.

    Google Scholar 

  • Holst PJ, Rosenkilde MM, Manfra D, Chen SC, Wiekowski MT, Holst B, et al. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J Clin Invest. 2001;108:1789–96. https://doi.org/10.1172/JCI13622.

    Google Scholar 

  • Jensen KK, Manfra DJ, Grisotto MG, Martin AP, Vassileva G, Kelley K, et al. The Human Herpes Virus 8-Encoded Chemokine Receptor Is Required for Angioproliferation in a Murine Model of Kaposi’s Sarcoma. J Immunol. 2005;174:3686–94. https://doi.org/10.4049/jimmunol.174.6.3686.

    Google Scholar 

  • Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma. J Virol. 1996;70:8218–23. https://doi.org/10.1128/jvi.70.11.8218-8223.1996.

    Google Scholar 

  • Chiou C-J, Poole LJ, Kim PS, Ciufo DM, Cannon JS, Ap Rhys CM, et al. Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2002;76:3421–39. https://doi.org/10.1128/JVI.76.7.3421-3439.2002.

    Google Scholar 

  • Cannon M, Philpott NJ, Cesarman E. The kaposi’s Sarcoma-Associated herpesvirus G Protein-Coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol. 2003;77:57–67. https://doi.org/10.1128/JVI.77.1.57-67.2003.

    Google Scholar 

  • Cannon ML, Cesarman E. The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells. Oncogene. 2004;23:514–23. https://doi.org/10.1038/sj.onc.1207021.

    Google Scholar 

  • Montaner S, Sodhi A, Servitja J-M, Ramsdell AK, Barac A, Sawai ET, et al. The small GTPase Rac1 links the Kaposi sarcoma–associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood. 2004;104:2903–11. https://doi.org/10.1182/blood-2003-12-4436.

    Google Scholar 

  • Shepard LW, Yang M, Xie P, Browning DD, Voyno-Yasenetskaya T, Kozasa T, et al. Constitutive activation of NF-κB and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus involve Gα13 and RhoA. J Biol Chem. 2001;276:45979–87. https://doi.org/10.1074/jbc.M104783200.

    Google Scholar 

  • Boon K, Vanalken N, Szpakowska M, Chevigné A, Schols D, Van Loy T. Systematic assessment of chemokine ligand bias at the human chemokine receptor CXCR2 indicates G protein bias over β-arrestin recruitment and receptor internalization. Cell Commun Signal. 2024;22:43. https://doi.org/10.1186/s12964-023-01460-2.

    Google Scholar 

  • Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature. 1997;385:347–50. https://doi.org/10.1038/385347a0.

    Google Scholar 

  • Geras-Raaka E, Varma A, Ho H, Clark-Lewis I, Gershengorn MC. Human Interferon-γ–inducible protein 10 (IP-10) inhibits constitutive signaling of kaposi’s Sarcoma–associated herpesvirus G protein–coupled receptor. J Exp Med. 1998;188:405–8. https://doi.org/10.1084/jem.188.2.405.

    Google Scholar 

  • Gershengorn MC, Geras-Raaka E, Varma A, Clark-Lewis I. Chemokines activate kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J Clin Invest. 1998;102:1469–72. https://doi.org/10.1172/JCI4461.

    Google Scholar 

  • Geras-Raaka E, Varma A, Clark-Lewis I, Gershengorn MC. Kaposi’s sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1α inhibit signaling by KSHV G protein-coupled receptor. Biochem Biophys Res Commun. 1998;253:725–7. https://doi.org/10.1006/bbrc.1998.9557.

    Google Scholar 

  • Rosenkilde MM, Kledal TN, Bräuner-Osborne H, Schwartz TW. Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem. 1999;274:956–61. https://doi.org/10.1074/jbc.274.2.956.

    Google Scholar 

  • Ho HH, Du D, Gershengorn MC. The N terminus of Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor is necessary for high affinity chemokine binding but not for constitutive activity. J Biol Chem. 1999;274:31327–32. https://doi.org/10.1074/jbc.274.44.31327.

    Google Scholar 

  • Rosenkilde MM, Schwartz TW. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. Mol Pharmacol. 2000;57:602–9. https://doi.org/10.1124/mol.57.3.602.

    Google Scholar 

  • Schwarz M, Murphy PM. Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-κB and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol. 2001;167:505–13. https://doi.org/10.4049/jimmunol.167.1.505.

    Google Scholar 

  • Pati S, Cavrois M, Guo HG, Foulke JSJ, Kim J, Feldman RA, et al. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of kaposi’s sarcoma pathogenesis. J Virol United States. 2001;75:8660–73. https://doi.org/10.1128/jvi.75.18.8660-8673.2001.

    Google Scholar 

  • Hensbergen PJ, Verzijl D, Balog CIA, Dijkman R, van der Schors RC, van der Raaij-Helmer EMH, et al. Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity. J Biol Chem United States. 2004;279:13402–11. https://doi.org/10.1074/jbc.M312814200.

    Google Scholar 

  • de Munnik SM, van der Lee R, Velders DM, van Offenbeek J, de Smits- Vries L, Leurs R, et al. The viral G protein-coupled receptor ORF74 unmasks phospholipase C signaling of the receptor tyrosine kinase IGF-1R. Cell Signal. 2016;28:595–605. https://doi.org/10.1016/j.cellsig.2016.02.017.

    Google Scholar 

  • Cornaby C, Tanner A, Stutz EW, Poole BD, Berges BK. Piracy on the molecular level: human herpesviruses manipulate cellular chemotaxis. J Gen Virol Microbiol Soc. 2016;97:543–60. https://doi.org/10.1099/jgv.0.000370.

    Google Scholar 

  • Couty J-P, Lupu-Meiri M, Oron Y, Gershengorn MC. Kaposi’s sarcoma-associated herpesvirus-G protein-coupled receptor-expressing endothelial cells exhibit reduced migration and stimulated chemotaxis by chemokine inverse agonists. J Pharmacol Exp Ther. 2009;329:1142–7. https://doi.org/10.1124/jpet.108.147686.

    Google Scholar 

  • Liu L, Doijen J, D’huys T, Verhaegen Y, Dehaen W, De Jonghe S, et al. Biological characterization of ligands targeting the human CC chemokine receptor 8 (CCR8) reveals the biased signaling properties of small molecule agonists. Biochem Pharmacol. 2021;188:114565. https://doi.org/10.1016/j.bcp.2021.114565.

    Google Scholar 

  • Schoofs G, Van Hout A, D’huys T, Schols D, Van Loy T. A flow Cytometry-based assay to identify compounds that disrupt binding of Fluorescently-labeled CXC chemokine ligand 12 to CXC chemokine receptor 4. JoVE. 2018;57271. https://doi.org/10.3791/57271.

  • Claes S, D’huys T, Van Hout A, Schols D, Van Loy T. A kinetic Fluorescence-based Ca2+ mobilization assay to identify G Protein-coupled receptor Agonists, Antagonists, and allosteric modulators. JoVE. 2018;56780. https://doi.org/10.3791/56780.

  • Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH, et al. Nanoluc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem Biol. 2016;11:400–8. https://doi.org/10.1021/acschembio.5b00753.

    Google Scholar 

  • Liu C, Sandford G, Fei G, Nicholas J. Ga protein selectivity determinant specified by a viral chemokine receptor-conserved region in the C tail of the human herpesvirus 8 G protein-coupled receptor. J Virol. 2004. https://doi.org/10.1128/jvi.78.5.2460-2471.2004.

    Google Scholar 

  • de Munnik SM, Kooistra AJ, van Offenbeek J, Nijmeijer S, de Graaf C, Smit MJ, et al. The viral G protein-coupled receptor ORF74 hijacks β-arrestins for endocytic trafficking in response to human chemokines. PLoS One. 2015;10:e0124486. https://doi.org/10.1371/journal.pone.0124486.

    Google Scholar 

  • Bogacka J, Pawlik K, Ciapała K, Ciechanowska A, Mika J. CC chemokine receptor 4 (CCR4) as a possible new target for therapy. Int J Mol Sci. 2022;23:15638. https://doi.org/10.3390/ijms232415638.

    Google Scholar 

  • Liu A, Liu Y, Llinàs Del Torrent Masachs C, Zhang W, Pardo L, Ye RD. Structural insights into KSHV-GPCR constitutive activation and CXCL1 chemokine recognition. Proc Natl Acad Sci U S A. 2024;121:e2403217121. https://doi.org/10.1073/pnas.2403217121.

    Google Scholar 

  • Park JB, Sahoo B, Sahoo AR, Kim D, Seo HD, Bowman J, et al. Structural basis for ligand promiscuity and high signaling activity of kaposi’s Sarcoma-associated Herpesvirus-encoded GPCR. Nat Commun. 2025;16:8403. https://doi.org/10.1038/s41467-025-63457-4.

    Google Scholar 

  • Rosenkilde MM, Kledal TN, Holst PJ, Schwartz TW. Selective elimination of high constitutive activity or chemokine binding in the human herpesvirus 8 encoded seven transmembrane oncogene ORF74. J Biol Chem. 2000;275:26309–15. https://doi.org/10.1074/jbc.M003800200.

    Google Scholar 

  • Feng H, Sun Z, Farzan MR, Feng P. Sulfotyrosines of the kaposi’s Sarcoma-Associated herpesvirus G Protein-Coupled receptor promote tumorigenesis through autocrine activation. J Virol. 2010;84:3351–61. https://doi.org/10.1128/JVI.01939-09.

    Google Scholar 

  • Zhang R, Xie X. Tools for GPCR drug discovery. Acta Pharmacol Sin. 2012;33:372–84. https://doi.org/10.1038/aps.2011.173.

    Google Scholar 

  • Zhang J, He S, Wang Y, Brulois K, Lan K, Jung JU, et al. Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPase. PLoS Pathog. 2015;11:e1004768. https://doi.org/10.1371/journal.ppat.1004768.

    Google Scholar 

  • Machleidt T, Woodroofe CC, Schwinn MK, Méndez J, Robers MB, Zimmerman K, et al. NanoBRET—a novel BRET platform for the analysis of Protein–Protein interactions. ACS Chem Biol. 2015;10:1797–804. https://doi.org/10.1021/acschembio.5b00143.

    Google Scholar 

  • Ma X, Leurs R, Vischer HF. NanoLuc-Based Methods to Measure β-Arrestin2 Recruitment to G Protein-Coupled Receptors. New York, NY: Springer US; 2021. pp. 233–48. https://doi.org/10.1007/978-1-0716-1221-7_16. G Protein-Coupled Receptor Screening Assays [Internet].

  • Luo J, Li D, Wei D, Wang X, Wang L, Zeng X. RhoA and RhoC are involved in stromal cell-derived factor-1-induced cell migration by regulating F-actin redistribution and assembly. Mol Cell Biochem. 2017;436:13–21. https://doi.org/10.1007/s11010-017-3072-3.

    Google Scholar 

  • Michaelis UR. Mechanisms of endothelial cell migration. Cell Mol Life Sci. 2014;71:4131–48. https://doi.org/10.1007/s00018-014-1678-0.

    Google Scholar 

  • Couty J-P, Geras-Raaka E, Weksler BB, Gershengorn MC. Kaposi’s Sarcoma-associated Herpesvirus G Protein-coupled Receptor Signals through Multiple Pathways in Endothelial Cells. J Biol Chem. 2001;276:33805–11. https://doi.org/10.1074/jbc.m104631200.

    Google Scholar 

  • Smit MJ, Verzijl D, Casarosa P, Navis M, Timmerman H, Leurs R. Kaposi’s sarcoma-associated herpesvirus-encoded G protein-coupled receptor ORF74 constitutively activates p44/p42 MAPK and Akt via G(i) and phospholipase C-dependent signaling pathways. J Virol. 2002;76:1744–52. https://doi.org/10.1128/jvi.76.4.1744-1752.2002.

    Google Scholar 

  • Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, Minina S, et al. Control of chemokine-guided cell migration by ligand sequestration. Cell. 2008;132:463–73. https://doi.org/10.1016/j.cell.2007.12.034.

    Google Scholar 

  • Décaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J Biol Chem. 2011;286:32188–97. https://doi.org/10.1074/jbc.M111.277038.

    Google Scholar 

  • Desnoyer A, Dupin N, Assoumou L, Carlotti A, Gaudin F, Deback C, et al. Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions. Br J Dermatol. 2016;175:1251–62. https://doi.org/10.1111/bjd.14748.

    Google Scholar 

  • Kwon E-K, Min C-K, Kim Y, Lee J-W, Aigerim A, Schmidt S, et al. Constitutive activation of T cells by γ2-herpesviral GPCR through the interaction with cellular CXCR4. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research. 2017;1864:1–11. https://doi.org/10.1016/j.bbamcr.2016.10.008.

    Google Scholar 

  • Nijmeijer S, Leurs R, Smit MJ, Vischer HF. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning. J Biol Chem. 2010;285:29632–41. https://doi.org/10.1074/jbc.M110.115618.

    Google Scholar 

  • Gouwy M, Struyf S, Noppen S, Schutyser E, Springael J-Y, Parmentier M, et al. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through Receptor-Mediated events. Mol Pharmacol. 2008;74:486–96. https://doi.org/10.1124/mol.108.045146.

    Google Scholar 

  • Lane BR, Liu J, Bock PJ, Schols D, Coffey MJ, Strieter RM, et al. Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi’s sarcoma. J Virol. 2002;76:11570–83. https://doi.org/10.1128/JVI.76.22.11570-11583.2002.

    Google Scholar 

  • Xu Y, Ganem D. Induction of chemokine production by latent kaposi’s sarcoma-associated herpesvirus infection of endothelial cells. J Gen Virol. 2007;88:46–50. https://doi.org/10.1099/vir.0.82375-0.

    Google Scholar 

  • Lee M, Lee J, Kang S, Wirth D, Yoo S, Park C. CXCL1 confers a survival advantage in Kaposi’s sarcoma-associated herpesvirus‐infected human endothelial cells through STAT3 phosphorylation. J Med Virol. 2023;95:jmv.28020. https://doi.org/10.1002/jmv.28020.

    Google Scholar 

  • Korbecki J, Bosiacki M, Szatkowska I, Kupnicka P, Chlubek D, Baranowska-Bosiacka I. The clinical significance and involvement in molecular cancer processes of chemokine CXCL1 in selected tumors. IJMS. 2024;25:4365. https://doi.org/10.3390/ijms25084365.

    Google Scholar 

  • Li X, Ohler ZW, Day A, Bassel L, Grosskopf A, Afsari B et al. Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of Kaposi sarcoma in patient-derived mouse models. BioRxiv. 2024. https://doi.org/10.1101/2024.09.27.615429. Cited 2025 Sep 9.

  • Knowlton ER, Rappocciolo G, Piazza P, Lepone LM, Nadgir SV, Bullotta A, et al. Human herpesvirus 8 induces polyfunctional B lymphocytes that drive Kaposi’s sarcoma. mBio. 2014;5:e01277-14. https://doi.org/10.1128/mBio.01277-14.

    Google Scholar 

  • Pontejo SM, Murphy PM, Pease JE. Chemokine subversion by human herpesviruses. J Innate Immun. 2018;10:465–78. https://doi.org/10.1159/000492161.

    Google Scholar 

  • Palande V, Roden RBS, Choi YB. Nano-luciferase complementation assay of human herpesvirus 8 chemo/cytokine-receptor interactions. Sci Rep. 2025;15:35365. https://doi.org/10.1038/s41598-025-19281-3.

    Google Scholar 

  • West J, Damania B. Upregulation of the TLR3 pathway by kaposi’s sarcoma-associated herpesvirus during primary infection. J Virol. 2008;82:5440–9. https://doi.org/10.1128/JVI.02590-07.

    Google Scholar 

  • Neumeyer S, Tagawa T. The Kaposi sarcoma herpesvirus control of monocytes, macrophages, and the tumour microenvironment. Virology. 2025;601:110286. https://doi.org/10.1016/j.virol.2024.110286.

    Google Scholar 

Continue Reading

  • ‘Superfluous consumerism’: adult Advent calendar trend alarms green groups | Christmas

    ‘Superfluous consumerism’: adult Advent calendar trend alarms green groups | Christmas

    The trend for Advent calendars aimed at adults is “superfluous consumerism” that adds to excessive and wasteful consumption, according to environmental groups.

    While once children excitedly opened a door each day to see what festive picture lay behind it, adults can now count down the days to Christmas with calendars containing everything from luxury beauty products to instant mashed potato.

    This year’s adult versions include beauty calendars such as the Nivea Women’s one at about £30 and one from Liberty priced at £275.

    But some have raised concerns over the packaging involved in providing 24 products to either be unwrapped or revealed each day, and the potential for unwanted items.

    Anna Diski, a plastics campaigner at Greenpeace UK, said: “Advent calendars like these probably contain two or three items you actually want, and 20 or so more you could do without. You don’t want that single-use plastic lingering in your bathroom cabinet, let alone in the natural environment.”

    Daniel Webb, the founder and director of the charity Everyday Plastic, said: “These luxury Advent calendars are a microcosm of a bigger problem, a system that keeps producing more and more stuff we don’t need and probably can’t afford.”

    The research firm Ipsos found seven in 10 Britons have a some point purchase an Advent calendar. While most bought chocolate ones (84%), beauty calendars are increasingly popular (15%), along with toy calendars (14%) and non-chocolate food versions (10%).

    The firm’s consumer intelligence platform, Ipsos Synthesio, has found online discussions around Advent calendars begin as early as September, driven by promotions by retailers and influencer-led unboxing videos.

    Webb said that encouraging people to shop for Christmas in the autumn was a decision “made by marketing departments, purely designed to drive overconsumption, not celebration”.

    He added: “I’m sure people find it fun and this isn’t about blaming anyone for wanting to celebrate – it’s about questioning why brands are choosing to fuel the waste crisis in this way. Real change means cutting plastic production and phasing out this kind of superfluous consumerism.”

    The beauty expert, journalist and author Sali Hughes said it was important to focus on asking “whether you would want at least five of the advent items if sold at full price”.

    She added: “If the answer is yes, then the whole calendar is probably worth the spend. If it’s no, then it’s a lot of money for the sake of novelty.

    “I also think it’s worthwhile imagining all the products in a pile, without the seductive packaging. If it consequently loses its allure, then you’re paying all that money for something pretty ephemeral that will, if its even been designed responsibly in the first place, just go into recycling after Christmas.”

    Samantha Dover, the insights director of beauty at the market analyst Mintel, said: “The adult Advent calendar trend isn’t going anywhere anytime soon, but the landscape in which these calendars sit is changing. In beauty, the high cost of many Advent calendars, even if they promise significant savings compared to buying individual products, means they are out of reach for many consumers.”

    Dover said the perceived savings mean they were still viewed as “good value for money”, adding: “It is likely that many consumers self-gift themselves calendars, and even split the cost with others and share products, as a result.” She said this could help reduce “waste often generated by Advent calendars”.

    Dr Christopher Carrick, the founder of bio-plastics manufacturer Lingin Industries, said government legislation was likely to have an impact on the calendars, which he described as “more packaging intensive, compared to the amount of actual product, than almost any other aspect of Christmas”.

    He said: “The extended producer responsibility which charges companies based on the amount of unsustainable packaging they put into the world is putting pressure on companies producing Advent calendars to reduce the amount of packaging.

    “This year, brands will have more responsibility over the costs associated with the waste generated by packaging, meaning designs and materials will need to be amended.”

    Continue Reading

  • X Introduces ‘About This Account’ Feature To Tackle Bots, Fake Profiles

    X Introduces ‘About This Account’ Feature To Tackle Bots, Fake Profiles

    To view your account details on either the X website or mobile app, you simply need to click on the “Joined” date displayed on your profile. This action opens a page that provides various pieces of information about your account, including the date you joined X, the location linked to your account, the number of times your username has been changed, along with the date of the last change, and how you accessed the platform, such as through the App Store or Google Play.

    Although users from various parts of the world have reported seeing the new feature appear on their own profiles, TechCrunch reported that it has not been able to view this account information on other users’ profiles. 

    This is likely because X is allowing account holders some time to review their displayed information for accuracy and make any desired changes to their settings before the feature is made available more widely.

    X offers users the option to choose whether their profile displays their specific country or just a broader geographical region. Initially, this choice was intended for users in countries where free speech protections are limited, but it appears that even users in the US can select between showing their country or their region or their continent. By default, the profile displays the country unless the user opts otherwise.

    Continue Reading

  • Navigating Shareholder Engagement and Shareholder Activism: Essentials and Best Practices

    Navigating Shareholder Engagement and Shareholder Activism: Essentials and Best Practices

    Engaging with shareholders and responding to shareholder activism continue to be top-of-mind for public companies. These situations present opportunities for management teams and boards of directors to work together to communicate the company’s strategy and reinforce the ways in which the company is positioned for lasting success. Our experience helping numerous clients engage with and respond to their shareholders has given us insight on the practices that stand out as the most effective.

    Shareholder Engagement

    A thoughtfully designed shareholder engagement program is a critical tool for public companies, including those companies who are newly public, who have multi-class capital structures, or both.

    What Is Shareholder Engagement and Why Is It Important?

    “Shareholder engagement” is the ongoing dialogue between a company and its shareholders. It involves targeted and thoughtful outreach, response, and disclosure with the goal of communicating the company’s value creation strategy and governance choices, learning investors’ perspectives and priorities, and building the company’s creditability with investors. Done right, it is a two-way dialogue between the company and its investors.

    From the investor perspective, shareholder engagement provides insight into information not captured in the company’s public filings, including the company’s position on emerging topics. It also gives an opportunity for investors to directly share their observations and preferences with boards and management teams.

    Shareholder engagement can provide an early warning of possible shareholder dissatisfaction, which could ripen into overt shareholder activism. In many ways, it is the proverbial “canary in the coal mine” for understanding investor concerns. When there is shareholder dissatisfaction, or when a company otherwise needs to solicit the support of shareholders, the foundation of trust and credibility built from multiple cycles of engagement can be invaluable.

    Who Should Engage with Shareholders?

    Shareholder engagement should be driven by the company’s management team. The functional lead is typically the company’s investor relations officer, who will usually participate in all shareholder engagement sessions to ensure consistency of messaging. A select group of the most senior executives (such as one or both of the Chief Executive Officer (CEO) and Chief Financial Officer (CFO)) typically participate in meetings with key shareholders, and potentially in all engagement meetings. Beyond this group, functional leads (such as the head of human resources or the head of diversity) can participate if the investor has expressed an interest in these topics. A small, well-coordinated team is best. Third-party advisors almost never participate in engagement sessions, as shareholders want to hear directly from the company and not from its advisors.

    Increasingly, shareholders are requesting meetings with board members—especially the board chair or lead independent director and the chair of the board’s compensation committee.

    Providing shareholders with access to board members is a strategic choice, and one that should be made only after reflection on the identity of the shareholder, the goals of the meeting, and a consideration of the right participants on behalf of the company (including as to which director is the best spokesperson). In all instances, board members should meet with shareholders only with the prior knowledge and approval of the board, only in close coordination with the management team, and only after thorough preparation.

    Which Shareholders Should We Engage With?

    There is no fixed rule on which shareholders a company should target for engagement. Many companies utilize rough metrics to size their engagement efforts, such as focusing on their top 25 institutional holders or trying to engage with the top 50 percent of their shareholder base. The right shareholders to engage will necessarily be company-specific and, sometimes, topic-specific; engagement will also evolve over time as the shareholder base changes. Overall, a reasonable goal is to offer to engage with a sufficiently meaningful number of shareholders so that the company gains the benefit of a diversity of shareholder perspectives, including in respect of a diversity of investing styles. To manage internal resources, it may be helpful to conduct outreach in phases (particularly if a company has not engaged historically) so that the number of engagement meetings in a short period is not overwhelming. Finally, shareholders beyond the target group also may approach the company to engage on matters of importance to them, and the company will need to consider its approach to engagement with these shareholders.

    The nature of the engagement may vary across shareholders. For example, many institutional investors funnel engagement through their “stewardship” or “governance” teams, with the portfolio manager not always participating in the meeting. Meetings with a governance team tend, not surprisingly, to be more focused on governance matters. In contrast, the portfolio manager may participate in engagement meetings with active managers. As such, these sessions may delve deeper into a company’s strategy and financials.

    At many companies, the rise of index investing has resulted in a concentration of voting power in the hands of a relatively small number of institutional investors. Index investors are more passive, long-term focused, and interested in better understanding a company’s long-term strategy. Companies ignore index investors at their peril, and regular efforts should be made to engage with the governance teams at these investors. More generally, institutional investors carefully track each company’s engagement efforts and may be less favorably inclined to support a company that only tries to engage in years when the company needs shareholder support for a non-routine voting matter.

    In 2025, BlackRock, Vanguard, and State Street—the largest index investors—split their governance teams to better align with how the assets are managed at each institution (active, passive, or sustainability). This could complicate engagement efforts in 2025 and 2026, with each pool of capital varying on a company-by-company basis and being managed by separate teams with different voting and engagement frameworks.

    It is often not a bad sign if a shareholder turns down an engagement offer. Shareholders receive a great deal of requests for engagement and must prioritize their time. A shareholder declining an engagement meeting typically means that the shareholder is satisfied with the company and does not feel that direct engagement is warranted at that time. Companies get credit with the shareholder for making the offer, even if the shareholder does not accept it.

    Should We Engage with Shareholders Who Are Known “Activists”?

    The answer is almost always yes. Activists are investors or prospective investors, and the best course is usually to treat them in the same way you treat similarly situated “friendly” investors. Engagement with an activist can provide valuable intelligence on the activist’s perspective and possible next steps. (See the “Shareholder Activism” section below for additional thoughts.)

    When Should We Engage with Shareholders?

    Shareholder engagement is an annual, year-round activity. The best time to meet with shareholders is typically from September to February. This period is often known as the proxy “offseason,” and is when investors typically have more timing flexibility, and thus may be more willing to accept an invitation for engagement. It also allows sufficient time for boards and management teams to incorporate shareholder feedback into decisions and disclosures for the next year.

    Newly public companies should aim to establish connections with shareholders early rather than waiting until the company has seasoned in the public markets. Engagement efforts during the first year after going public can yield substantial dividends in ensuing years, both in building institutional capability and in developing relationships.

    How Should We Conduct a Meeting with Shareholders?

    Shareholders should leave an engagement meeting with the belief that the company was open to their views and honestly wants to hear and understand their concerns.

    Shareholder engagement meetings are typically scheduled for 30 minutes to one hour. The company should prepare, and send to the shareholder in advance, an agenda that lays out the key topics for the meeting; this can keep the discussion on track. It can be helpful to have someone take notes for the company’s use during the meeting.

    The company’s representatives should conduct the meeting and drive the discussion. Shareholders want to engage directly with the decisionmakers, so top management or a board member should be the company’s primary speakers. Throughout the meeting, the company will want to show that its participants have a strong command of the issues facing the company. Although not mandatory, executives generally engage most in discussions related to their functional areas. For example, the CEO would concentrate on questions and discussion related to strategy and “big picture” items, the CFO would focus on financials, and the General Counsel would focus on governance. Throughout the meeting, it is important for the company’s participants to demonstrate competence, alignment, and engagement.

    Approach the meeting as a discussion and not a negotiation. This means listening actively and soliciting feedback, and not being dismissive, defensive, or confrontational. It is natural for there to be issues on which the company and the shareholder disagree, but the company’s focus in the meeting should not be on trying to change the shareholder’s mind. Rather, the goal is to clearly and unemotionally communicate the company’s position, reasoning, and value creation strategy while also building credibility with shareholders.

    How Do We Prepare for an Engagement Meeting?

    Preparation is key for any shareholder meeting. Major preparatory work typically involves:

    • Assembling the engagement team. The investor relations officer often quarterbacks the engagement effort, with contributions and assistance from individuals in the finance, corporate strategy, and legal functions.

    • Reviewing the shareholder’s voting policies and guidelines (which are typically publicly disclosed), and how the shareholder has voted at the company historically. Mutual funds, registered investment companies, and persons required to make filings on Form 13F are generally required to file a Form NP-X, which contains information on how the investor voted at each company. There are several third-party services that collate Form NP-X data into an easy-to-digest format. Also important is developing an understand of who the key decision makers are at each investor, how to contact those persons, and what authority they have to “override” the investor’s general governance policies.

    • Benchmarking how the company’s practices compare to the shareholder’s voting policies and guidelines, if publicly disclosed.

    • Understanding who from the shareholder will participate in the meeting. Be aware that the meeting may be dominated by individuals from the investor’s governance team, and these individuals may have limited knowledge about the company or its business. In that regard, presenting a brief, one- or two-minute primer on the company at the outset may be helpful to orient the conversation.

    • Preparing the right talking points to articulate the company’s value creation strategy and governance practices, and how those compare to the shareholder’s policies and areas of interest.

    • Understanding aggregate historical voting patterns at the company, such as a failed “say-on-pay” vote and the reasons behind it.

    • Understanding several years of recommendations proxy advisory firm recommendations at the company and how these recommendations impact the vote at prior shareholder meetings.

    • Deciding on a strategy for how to proactively address tough topics, such as a failed say-on-pay vote. Although it can be tempting to hope that shareholders will not ask challenging questions or inquire about topics that are awkward for the company to discuss, it is typically better to proactively raise these items. Doing so builds credibility with shareholders, as it does not seem like the company is trying to “hide the ball.” Addressing tough topics can also “open the door” for the investor to engage in the discussion, which may be helpful given the guidance from the U.S. Securities and Exchange Commission (SEC) (see next section, “What Are the Legal Requirements to Be Aware Of?”).

    • Developing sample questions and answers to anticipate and respond to shareholder questions. Providing clear, succinct answers—instead of non-answers—is the best approach.

    • Preparing appropriate written materials to distribute in advance of the meeting. This is typically a tailored version of the company’s normal investor presentation, with additional information (often from the proxy statement) added on topics such as governance and executive compensation.

    Many companies—particularly as they are building experience with shareholder engagement, or where top management or a board member are participating—hold a “dress rehearsal” in advance of the meeting. This can be an effective way to ensure messaging consistency, develop natural hand-offs between participants, and allocate who will cover which topics.

    What Are the Legal Requirements to Be Aware Of?

    All communications with shareholders need to be made in compliance with Regulation FD, and shareholder engagement meetings are no exception. Some investors may seek to test the bounds of the company’s Regulation FD compliance, and the company’s participants may need to, politely but firmly, prevent the conversation from straying beyond what the company has already publicly disclosed or is prepared to publicly disclose.

    A shareholder is under no obligation to keep confidential the discussion in an engagement meeting. As such, the company’s participants in an engagement meeting should not say anything that they would not want to see in a subsequent letter from the shareholder to the company’s shareholders or in a press release issued by the shareholder.

    Generally, written materials provided to shareholders in engagement meetings are not required to be filed with the SEC as soliciting material so long as they are used in meetings held prior to the company filing its preliminary or definitive proxy statement. (To meet the company’s Regulation FD obligation, it may be necessary to file these materials with the SEC or post them on the company’s website.) Once a proxy statement is on file, the practice is to file written materials with the SEC because they may be soliciting material; in addition, filing at this time allows for widespread distribution of these materials to other shareholders at a time when the company is soliciting proxies. It is typically not necessary to retrieve any written materials distributed in advance of or at an engagement meeting.

    In early 2025, the SEC staff revised its guidance on how engagement with companies may affect a beneficial owner’s active/passive status for purposes of filings on Schedule 13G and Schedule 13D. Previously, engagement on topics such as ESG, staggered boards, poison pills, or executive pay was not deemed to be inconsistent with an investor maintaining its status as a Schedule 13G filer. Under the revised guidance, generally, an investor who describes its views and how it may inform voting decisions, without more, can still use Schedule 13G.

    Although compliance with the beneficial ownership reporting rules is ultimately a matter for the shareholder, this new guidance resulted in some investors pausing their engagement meetings for a period. We believe that investors have adjusted to this new guidance. Anecdotally, we have heard that it has resulted in investors expressing greater preference for the company to take the lead in framing the conversation (see previous section, “How Should We Conduct a Meeting with Shareholders?”) for more discussion on how an agenda provided by the company can be helpful) and for more investors to be in a “listen-only” posture. Some investors have also started to read a scripted engagement disclaimer at the beginning of a meeting. Even if an investor reads this type of script, we do not recommend altering how the company approaches the meeting.

    What Should Be the Goals for Engagement?

    The most important objective of shareholder engagement is the exchange of perspectives between the company and its investors. We believe that engagement meetings work best when they are a two-way dialogue, even if the two sides are not in alignment on what the company should do.

    Beyond exchanging ideas, companies may have a variety of objectives for engagement, and these objectives can impact how a company approaches the meeting.

    • Some companies may be engaging as a matter of good corporate hygiene and may not have a goal beyond simply meeting with shareholders. In this case, the engagement may be on high-level topics that are not especially tailored to the shareholder, with the goal primarily to keep the lines of communication open.

    • Other companies may be engaging to try to build or repair a relationship. These discussions will likely have a more focused agenda than a general engagement meeting, with the goal of a frank exchange of perspectives.

    • Still other companies may be gathering shareholder input on one or more issues, such as investor perspectives on the company’s pay practices. The goal of these meetings is for the investor to do more of the talking by providing its perspective and rationale.

    What Should We Do After We Engage?

    Post-meeting follow-up is often overlooked. Companies should promptly satisfy any commitments (such as providing additional information) made during the meeting. One or more meetings of the company’s engagement working group to discuss the results of the engagement, either after key meetings or at the end of the engagement cycle, can be useful to share impressions, agree on takeaways, and plan for the future.

    We recommend that management teams be transparent with their boards of directors about the results of engagement efforts. This means providing the board with the unvarnished perspectives received, even if these perspectives are not universally flattering to the company, management, or the board. Sharing candid feedback allows the board to understand how investors see the company and consider whether change is warranted. It avoids a circumstance where the board is, in the future, surprised to learn of investor dissatisfaction. Especially in the shareholder activism context, this type of surprise can generate mistrust between the board and management team at precisely the time when trust between these two groups is critical.

    After gathering shareholder feedback and informing the board, the board and management team should review the feedback to determine if adjustments to the company’s strategy, governance, compensation practices, or other areas are necessary. If changes are determined to be warranted, the board and management team should establish a timeline and implementation approach, as well as the right way to communicate these changes to investors. Ultimately, gathering feedback is futile if the company is not going to use that feedback to inform its decision-making.

    What Are Other Best Practices?

    Shareholder engagement is good governance, and companies benefit from being transparent about their engagement efforts. Many companies disclose details on the number of shareholders contacted, the number of meetings held, the feedback received, and the actions taken in response to the feedback. Some companies even include “what we heard, what we did” charts and summaries in their proxy statements. These charts and summaries describe the nature of shareholder feedback received over the course of the year and detail how the company responded to that feedback. Even if this detailed disclosure is not included in the proxy statement, it can be helpful to organize the information in this manner for purposes of discussions with the board and its committees. This information requires careful recordkeeping and tracking of investor interactions—a job that often falls to the legal team if a company does not yet have a robust investor relations function.

    When reporting on shareholder feedback, do not ignore hard feedback. Although it is tempting to not publicly acknowledge areas where there is disagreement between the company and investors, it is— similar to addressing tough topics in the engagement meetings—often better to address these items head on and explain why the company made the choices that it did. For example, if shareholders are unsatisfied with the executive compensation program, use the engagement disclosure to explain the company’s view on why the program is appropriate. This shows that the company listened to—and understood—the feedback. Shareholders do not expect companies to meet every request, but they do expect to see that the company listened and has a defensible approach for its choices.

    Shareholder Activism

    Shareholder activism is a fact of life for public companies. Activism is its own asset class, with billions of dollars allocated to investors who pursue “activist” strategies. Shareholder engagement can be helpful in anticipating and understanding shareholder activism, but it cannot eliminate it.

    What Is Shareholder Activism?

    “Shareholder activism” occurs when shareholders use their ownership rights in a company to influence its board and management to make changes to the company’s policies, operations, or strategic direction. Broadly speaking, shareholder activism exists on a spectrum, with governance-focused activists (especially those who frequently utilize the SEC’s Rule 14a-8 process) on one end and financial activists (such as hedge funds) on the other end. Financial activists are the focus of the thoughts below.

    What Is the Current State of Shareholder Activism?

    Shareholder activism continues to be a significant challenge to a company’s policies and practices. Every company (even if it has significant friendly shareholders or a multi-class capital structure) is vulnerable to activism in some way, with that vulnerability increasing and decreasing depending on the company’s circumstances.

    A shareholder activist’s goal is to find a catalyst to increase a company’s stock price, which translates into money for the activist. A frequent catalyst is that the company should engage in a significant transaction, such as a sale of a division or the entire company. Beyond M&A, activists often focus on the company’s capital structure (including whether it is properly levered), its capital return practices (both as to dividends and share repurchases), operations and strategy (such as ways to improve profitability), and board composition (including whether there are directors who bring a “shareholder’s perspective” to the boardroom).

    Shareholder activists constantly evolve their tactics. Many activists are now willing to engage in multiyear campaigns, and some have shown a willingness to attack companies that fended off or settled with an activist in the recent past. We have also seen an increase in the number of activism campaigns that explicitly target the company’s CEO for replacement (including with the activist presenting its own CEO candidate) or question the board’s succession planning efforts. There also does not seem to be an “off-season” for activism, with activists showing a willingness to approach a company at any time of the year—even shortly after the shareholder meeting.

    The SEC’s universal proxy card rules provided activists with a fresh tactic to use against companies. These rules significantly increased the focus on the qualifications of each director. There is now a greater premium on explaining why each director serves on the board (for example, explaining the unique skills that each director brings). Further, universal proxy allows activists to “target” individual directors for replacement, which has resulted in greater vulnerability for directors with long tenures or who are older than 75, or who are “overboarded” or have attendance concerns. Although the universal proxy rules do not seem to have improved the overall success that activists have in proxy contests, they do seem have increased the number of settlements with activists. (See section below, “How Should We Think About Settlement with an Activist?”)

    How Should We Prepare for Shareholder Activism?

    The issues, tactics, challenges, and approaches in a shareholder activism situation will vary based on many factors, including the company, board dynamics, and the identity of the activist. That said, we believe that a thoughtful and well-executed shareholder engagement strategy is the best way to prepare for shareholder activism. As described above, the goal of shareholder engagement is to communicate the company’s value creation strategy and governance choices, learn investors’ perspectives and priorities, and build the company’s credibility with investors.

    Beyond engagement, the board of directors, in partnership with the management team, should frequently review the company’s strategy and operations (including the metrics used to make and evaluate decisions), approach to balancing growth and profitability, margin priorities, and other key business indicators. It is often said that boards should “think like an activist,” and this can be a useful construct for examining the business in a different way. For example, are there value creation strategies that the company could pursue? If so, should they be pursued, on what timeframe, and how should that be communicated to investors? If they should not be pursued, why not, and how should that be communicated? This work can help ensure alignment between the board and management team—and expose areas where additional analysis and discussion is needed to create that alignment.

    Regular board refreshment can be evidence of a healthy board dynamic and a willingness by the board to include new perspectives. Proactive board change can blunt an activist’s argument that the board is entrenched. To this end, maintaining a robust board succession plan and pipeline of director candidates can be very beneficial.

    Although governance rarely precipitates activism, it can serve as a wedge issue. Activists frequently claim that governance practices that they oppose—such as staggered boards—are evidence of a board that is entrenched and out-of-touch with shareholder desires. Regular reviews of the company’s governance policies and practices, along with frank conversations at the board level about whether they should evolve, are important preparatory work. Similarly, regular reviews of structural measures— such as advance notice bylaws to ensure that they are state-of-the-art—are good practice. At the same time, boards should be cautious about simply adopting “one-size-fits-all” governance practices (which are often advocated for by activists), as they practices may not be right for the company.

    Proactively assembling an activism response team—composed of key internal team members, outside counsel, a trusted financial advisor, a crisis communications firm, and a proxy solicitor—can save time and ensure that the company is able to respond rapidly to activism. This team should assemble and update a “break glass” response plan to be used if an activist targets the company. This plan is meaningfully bolstered if the team also takes the time to think through the key arguments that an activist could make in attacking the company and develop responses to those arguments. Although the final details of the company’s response will necessarily depend on the facts that exist at the time that the response is required, having draft materials can provide the company with a significant timing benefit. Activists frequently leverage their ability to strike quickly and with limited internal process to attempt to set and control the narrative. Advance work by the company can quicken its ability to respond.

    Interpersonal connections among the members of the response team can be valuable in responding to an activist challenge. To keep these connections strong and maintain preparedness, the response team should collectively conduct periodic “fire drills” and vulnerability assessments. Continuing to refine the company’s responses to a hypothetical activist challenge is important ongoing work for the response team, as is understanding the strategies and tactics of investors who have made activist approaches to other companies (especially those in the same industry).

    Companies should keep their eyes and ears open to investor perspectives communicated outside of formal engagement. For example, similar questions asked by different investors on earnings calls can be a sign of building investor consensus that should be understood. Robust investor surveillance efforts, including a stock watch service, can provide an early warning of an activist stock accumulation. Shareholders moving some of their holdings onto the transfer agent’s records—rather than holding beneficially through a bank or broker—can also be a telling sign that activism may be coming.

    Do Companies with Multi-Class Capital Structures Need to Think About Activism?

    Yes. Multi-class companies are often household names, and activism at these companies garners significant public attention. Even if the activist does not have a path to achieving its objectives, a campaign could generate significant publicity for the activist, in addition to positioning the activist for future fundraising efforts.

    How Should the Board Be Involved in Responding to Shareholder Activism?

    We think that the board and management team should see themselves as equal partners in addressing activism. This requires a frank and open dialogue between these groups about the company and its challenges and opportunities. As part of that, management should keep the board regularly updated about activism preparation and response. Ongoing director education—such as presentations by outside counsel on evolving activist tactics and the company’s vulnerabilities—can be helpful in demonstrating to the board that the management team has the company well-prepared for activism. The reputation and professional qualifications of directors are frequently attacked by activists. Activist attacks can be unnerving, and directors want to understand what the company will do in response. In addition, a unified board on key strategic issues is essential to successfully managing an activist attack, and it is hard to build and maintain that unity if directors do not feel that they have been kept informed. A lack of information provided to the board can further a frequent activist goal, which is to drive a wedge between management and the board by causing the board to question the company’s strategy management’s performance.

    Regular board updates are equally important when a company is actively engaging with an activist. The board should always have enough information to fulfill its oversight obligation, and we have found that directors are eager to understand how the company’s advisors and management team are approaching the situation. Some directors may also be called on to meet with the activist and will need to understand the entire state of play. Said differently, not involving the board in activism response has the potential to create a separation between management and the board at precisely the time when those two groups must be most aligned.

    Does the Board Need to Form a Special Committee to Respond to an Activist?

    Generally, a special committee is not necessary. The entire board has an inherent interest in the outcome, which means that there is typically no conflict of the type that would give rise to the need for a special committee. In addition, a special committee necessarily divides the board—at precisely the moment when an activist is seeking to do the same.

    How Should We Respond to An Activist?

    It is most common for activists to initially approach a company privately to express their concerns and plant the seeds for change. The company and the activist may disagree on many things, and engagement may seem futile—especially if the activist is strident in its criticisms. We think that it is a strategic mistake for a company not to engage robustly with an activist while the situation remains private, as keeping the situation private for as long as possible has significant advantages for the company. In addition, many investors expect companies to engage with activists with the goal of constructively working through their differences. But for the engagement to have a chance at being successful, the activist will want to know that 1) its views are being taken seriously and 2) the board is open to change, not asleep at the wheel, and not willfully blind to potential alternatives. This requires careful and frequent coordination between the board, the management team, and the company’s advisors to ensure that the right messages are being delivered in the right sequence.

    If private engagement fails, the activist may choose to make its criticisms public (or the activist may have chosen to go public from the outset). The company’s posture remains the same in a public attack: it should reinforce that the board is open-minded, takes shareholder feedback seriously, and is focused on building shareholder value. A public activism situation tends to be similar to a political campaign, with each side jockeying for shareholder support and to control the narrative. Companies do better in these situations when they take the high road and show that the board is sober, deliberative, and open to change, but also able to move quickly when circumstances warrant.

    Where Do Companies Go Wrong with Activists?

    Each activism situation is unique, and it is impossible to script how it will resolve or what direction it will go. That said, we think that companies have less success when:

    • the board and management team fail to speak with one voice (debate should be open and vigorous in the boardroom, but the board and management must be aligned publicly once a decision is made);

    • they are dismissive of the activist;

    • they implement a “scorched earth” defense, including by trying to be as aggressive as, or more aggressive than, the activist; and

    • they take things personally and allow decisions to be clouded by emotion.

    Engagement with an activist is asymmetric: shareholders will tolerate an activist doing and saying things about the company to a far greater extent than they will tolerate a company doing or saying similar things about the activist. In any activism response, the board should continually ask itself whether a proposed action will earn it more shareholder support than not taking the action and make decisions accordingly.

    How Should We Think About Settlement with an Activist?

    An activist’s ultimate leverage is to conduct a proxy contest to replace some or all of the members of the board. Directors who are nominated by an activist and elected by shareholders join a board with a mandate for change, and this can have a powerful impact on boardroom dynamics; this is true even at companies with classified boards where an activist can only elect a few directors each year. In addition, a proxy contest is disruptive to employees, customers, and other constituencies, will occupy a significant amount of board and management time and attention, and is costly.

    Given these factors, boards often look to resolve—or “settle”—an activism campaign before it evolves into a proxy contest through some type of negotiated compromise. These settlements can take many forms, but most often include some change to the composition of the board and the implementation of some aspects of the activist’s strategy (such as increased capital return or operational improvement initiatives). Companies can unilaterally adopt some or all of the activist’s requested changes without reaching a negotiated resolution with the activist; the objective of this strategy is to erode support for the activist among other shareholders by showing that the board is its own change agent and does not need outside pressure (or new directors chosen by the activist) to take bold action. Dialogue with other shareholders during the campaign can be helpful in understanding how they view the company and the activist’s critiques.

    There is no precise “right time” for when a company should pursue settlement. The leverage can change—favorably and unfavorably—as the campaign evolves. In some situations, the activist’s demands will be wrong for the company, and fighting the activist all the way to the shareholder meeting is the right decision. In others, a settlement can allow the company to return its full attention to execution. Overall, boards are well served when they are prepared to go the distance but flexible in their thinking about possible offramps to an activism campaign.

    Continue Reading